- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Current Advances in Continuous Glucose Monitoring Technology
CGMs have revolutionized diabetes management for patients and healthcare providers alike. This slide show summarizes the most recent enhancements.
Continous glucose monitors (CGMs), technology designed to improve glycemic control and quality of life for persons with diabetes, received a flurry of FDA appprovals in 2018.
Since then, the FDA-approved CGMs have benefited from a variety of enhanced features, new applications, and new approvals that promise to further advance the management of diabetes and thus the functioning and quality of life of those living with the disease.
Scroll through the slides below for concise summaries of the key original CGM approvals and features and the innovations and advances that have been approved since.
Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting
October 14th 2024Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.
